| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 10/26/2006 | US20060241044 Encoding delta-endotoxins having pesticidal activity against insect pests such as Lepidoptera |
| 10/26/2006 | US20060241043 Bacillus Cry9 family members |
| 10/26/2006 | US20060241042 Calcineurin activators |
| 10/26/2006 | US20060241041 Fvii or fviia gla domain variants |
| 10/26/2006 | US20060241039 reduce blood clotting activity by reducing thrombin generation; thrombotic diseases |
| 10/26/2006 | US20060241036 Soluble human interleukin 18 receptor-alpha, method of assaying the same, assay kit and medicinal composition |
| 10/26/2006 | US20060241035 Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome |
| 10/26/2006 | US20060241034 Means for preventing and treating cellular death and their biological applications |
| 10/26/2006 | US20060241032 Cell support comprising immobilized collagen/intergin fusion and a argine-glycine-aspartic acid (RGD) motif for use as scaffold to propagate implant or transplant materials; improving drug delivery systems; inhibition of tumor metastasis; tissue engineering |
| 10/26/2006 | US20060241030 Irs modulators |
| 10/26/2006 | US20060241028 Respiratory system disorders; lung hypotensive agents; also pituitary adenylate cyclase activating peptide |
| 10/26/2006 | US20060241027 Hiv inhibiting proteins |
| 10/26/2006 | US20060241026 Novel cyclic peptides and use thereof as anti-microbial agents |
| 10/26/2006 | US20060241022 Selectin targeting bioconjugates |
| 10/26/2006 | US20060241020 Protein tyrosine phosphatase inhibitors |
| 10/26/2006 | US20060241019 Long lasting insulin derivatives and methods thereof |
| 10/26/2006 | US20060241018 Linkers for radiopharmaceutical compounds |
| 10/26/2006 | US20060241016 For isolating low molecular weight peptides from animal tissue; prevention of initial dissolution of higher molecular weight fraction proteins by in situ denaturation within the tissue, by an organic solvent (preferably ethanol), prior to aqueous extraction |
| 10/26/2006 | US20060241015 Cancer genes |
| 10/26/2006 | US20060240567 Method of immobilizing a protein to a zeolite |
| 10/26/2006 | US20060240561 Biomarkers for diagnosing alzheimer's disease |
| 10/26/2006 | US20060240559 5-hydroxytryptamine transporter gene polymorphisms |
| 10/26/2006 | US20060240530 cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles |
| 10/26/2006 | US20060240526 Amino acid substitution in position 36; brain bleeding, hemorrhage, trauma or injury; genetic engineering and expression; biodrugs, anticoagulants |
| 10/26/2006 | US20060240525 Factor VII or VIIa - Like Molecules |
| 10/26/2006 | US20060240524 Conjugate comprising polypeptide with N-glycosylation site and sugar; increase blood clot formation for treatment of thrombocytopenia and hemophilia |
| 10/26/2006 | US20060240523 Endogenous and non-endogenous versions of human G protein-coupled receptors |
| 10/26/2006 | US20060240522 Process for bacterial production of polypeptides |
| 10/26/2006 | US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity |
| 10/26/2006 | US20060240519 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 10/26/2006 | US20060240517 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240514 Fermentation of product for growth medium with reduced levels of animal meat or dairy product |
| 10/26/2006 | US20060240512 Inducing oocyte activation by administering sperm perinuclear theca protein 34; interacts with tyrosine kinase; enhancing fertility; treating or diagnosing diminished fertility and abnormal spermiogenesis, providing contraception; identifying contraceptive and fertility-enhancing agents |
| 10/26/2006 | US20060240511 a DNA fragment that encodes an immunogenic variant of human estrogen receptor-2 (HER-2) polypeptide, a EGFR (endothelial growth factor receptor) family of proteins, capable of raising an immune response in humans; vaccines |
| 10/26/2006 | US20060240510 Method for designing peptides |
| 10/26/2006 | US20060240503 Protease detection assay |
| 10/26/2006 | US20060240501 Removing fructosyl group from a fructosylated peptide or protein by reacting with an aqueous Pyrus pyrifolia, Vitis vinifera, or Daucus carota extract containing an enzyme that removes the fructose without removing an amino acid residue; detecting reaction products |
| 10/26/2006 | US20060240500 Diagnosis of kidney damage and protection against same |
| 10/26/2006 | US20060240496 Immunogens, derivatives and immunoassay for ethyl glucuronide |
| 10/26/2006 | US20060240494 Biocidal molecules, macromolecular targets and methods of production and use |
| 10/26/2006 | US20060240491 Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection |
| 10/26/2006 | US20060240477 polypeptide comprising a symmetrical dimethylated arginine, is used for diagnosing systemic lupus erythematosus |
| 10/26/2006 | US20060240474 Peptides able to switch between two structural states and their use |
| 10/26/2006 | US20060240472 Pigment protein |
| 10/26/2006 | US20060240465 CNG2B: a novel human cyclic nucleotide-gated ion channel |
| 10/26/2006 | US20060240464 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 10/26/2006 | US20060240455 Oxazine derivatives |
| 10/26/2006 | US20060240446 Novel human cytomegalovirus DNA sequences |
| 10/26/2006 | US20060240425 Genes and polypeptides relating to myeloid leukemia |
| 10/26/2006 | US20060240424 Regulation of human p2y15 g protein-coupled receptor |
| 10/26/2006 | US20060240421 Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy |
| 10/26/2006 | US20060240418 Canine gene microarrays |
| 10/26/2006 | US20060240417 Agent controlling the apoptosis induction by p73 |
| 10/26/2006 | US20060240414 Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| 10/26/2006 | US20060240114 Drug for treating hemophilia and method of treating hemophilia using the same |
| 10/26/2006 | US20060240113 Anticancer agents; prevent forming blood vessels; removal blockager |
| 10/26/2006 | US20060240058 Combinatorial surface chip compositions for selection, differentiation and propagation of cells |
| 10/26/2006 | US20060240045 Neisserial vaccine compositions comprising a combination of antigens |
| 10/26/2006 | US20060240044 Streptococcal superantigens spe-l and spe-m |
| 10/26/2006 | US20060240041 PRRSV Vaccines |
| 10/26/2006 | US20060240040 Optimized expression of hpv 45 l1 in yeast |
| 10/26/2006 | US20060240036 I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis |
| 10/26/2006 | US20060240035 Vmp-like sequences of pathogenic borrelia species and strains |
| 10/26/2006 | US20060240034 Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats |
| 10/26/2006 | US20060240030 Anti-hiv immunogenic formulation and process for preparation thereof |
| 10/26/2006 | US20060240029 Chlamydia pneumoniae antigens |
| 10/26/2006 | US20060240028 Anti-nls substances and uses thereof in nuclear import inhibition |
| 10/26/2006 | US20060240025 isolated polypeptide encoded by an isolated nucleic acid molecule as antitumor biodrugs; modulation of chemokine, cytokine expression |
| 10/26/2006 | US20060240023 Apoptosis-associated protein and use thereof |
| 10/26/2006 | US20060240022 Factor involved in metastasis and uses thereof |
| 10/26/2006 | US20060240021 Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes |
| 10/26/2006 | US20060240018 Artificial antibody polypeptides |
| 10/26/2006 | US20060240017 IgG4 constant region; antigen-binding Fab' fragment; antibody or antigen binding fragment competitively inhibits binding of A2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha |
| 10/26/2006 | US20060240004 Methods for treating tweak-related conditions |
| 10/26/2006 | US20060239998 Prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII; antihemophilic factor inhibitors; monoclonal cell lines expressing such anti-idiotypic antibodies; monoclonal cell lines expressing such anti-idiotypic antibodies |
| 10/26/2006 | US20060239997 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 10/26/2006 | US20060239988 Neuronal regeneration and compound administration methods |
| 10/26/2006 | US20060239984 Promoter to il-18bp, its preparation and use |
| 10/26/2006 | US20060239978 Cellular expression of 65B13 in the neurons can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease |
| 10/26/2006 | US20060239972 Adiponectin gene therapy |
| 10/26/2006 | US20060239969 Isolated nucleic acid molecule; enhancing immunity to the protein product expressed by the HER2/neu tumor-associated antigen |
| 10/26/2006 | US20060239968 method of delivering agent to prostate cancer tissue comprising obtaining peptide that selectively binds to prostate cancer tissue, where peptide is less than 100 amino acids in length and includes prostate cancer targeting motif having disclosed amino acid sequence; peptide is attached to target agent |
| 10/26/2006 | US20060239967 Oncolytic virus replicating selectively in tumor cells |
| 10/26/2006 | US20060239965 Fusion polypeptide comprising a hyaluronan-binding polypeptide fused to a heterologous polypeptide such as a growth factor, an enzyme that activates a prodrug, an angiogenesis inhibitor, a chemoattractant polypeptide or a matrix metalloproteinase inhibitor; anticancer agents |
| 10/26/2006 | US20060239914 bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy |
| 10/26/2006 | DE102005019104A1 New conjugate of fluorescent dye bonded directly to protein, useful for intraoperative representation of tumors, inflammation and lymph nodes |
| 10/26/2006 | CA2608410A1 A novel .beta.-galactoside-.alpha.2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof |
| 10/26/2006 | CA2605964A1 High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies |
| 10/26/2006 | CA2605410A1 A therapeutic agent for a .beta. related disorders |
| 10/26/2006 | CA2605402A1 Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| 10/26/2006 | CA2605250A1 Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof |
| 10/26/2006 | CA2605038A1 Mammalian expression systems |
| 10/26/2006 | CA2605037A1 Hgf beta chain variants |
| 10/26/2006 | CA2604933A1 Methods and compositions for modulating and detecting wisp activity |
| 10/26/2006 | CA2604925A1 Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| 10/26/2006 | CA2604732A1 Vaccine against pandemic strains of influenza viruses |
| 10/26/2006 | CA2604705A1 Porcine circovirus and helicobacter combination vaccines |
| 10/26/2006 | CA2604604A1 Methods for treating and preventing fibrosis by il-21 / il-21r antagonists |
| 10/26/2006 | CA2604580A1 Methods for modulating bone formation and mineralization by modulating krc activity |